NICE: Roche : NICE says Roche's skin cancer drug not cost effective

(4-traders.com) The National Institute for Health and Care Excellence (NICE) does not recommend cobimetinib (Cotellic, Roche) with vemurafenib (Zelboraf, Roche) for people with advanced BRAF V600 mutation-positive melanoma that has spread and can't be surgically removed. The committee agreed the combination offers life extending benefit compared to vemurafenib...http://www.4-traders.com/ROCHE-HOLDING-LTD-9364975/news/Roche-NICE-says-Roche-s-skin-cancer-drug-not-cost-effective-23013179/